Overview

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
This is a single-center, Phase I, healthy adult subject study with a randomized, double blind, three period, three-treatment, cross-over design.
Phase:
Phase 1
Details
Lead Sponsor:
Pearl Therapeutics, Inc.
Treatments:
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate
Glycopyrrolate